The global vagus nerve stimulation market size was valued at $488.5 million in 2022, and is projected to reach $836.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.
Vagus nerve stimulation (VNS) is a medical treatment that involves the use of electrical impulses to stimulate the vagus nerve, which is a large nerve that runs from the brainstem to the abdomen. The vagus nerve is responsible for regulating many important physiological functions, including heart rate, digestion, and breathing. The implantable device is typically implanted under the skin in the chest or neck, and a wire is attached to the vagus nerve. The electrical impulses generated by this device can help to regulate various physiological functions in the body, including heart rate, breathing, and digestion. VNS therapy is currently used to treat several medical conditions, including epilepsy, depression, and migraine.
VNS is generally considered safe and well-tolerated, although there are some side effects such as hoarseness, coughing, change in voice, and neck pain. These devices are of two types such as implantable VNS devices and externally VNS devices. Vagus nerve stimulation has been FDA-approved treatment for epilepsy and depression. In addition, compared to traditional medications, electrical stimulation of nerves can offer several advantages, such as targeted and adjustable stimulation, reduces risk of systemic side effects, and the potential for long-term benefits.
The global vagus nerve stimulation market is majorly driven by rise in number of people suffering from epilepsy and rise in technological advancements in vagus nerve stimulation devices. For instance, in 2021, Centers for Disease Control and Prevention (CDC), estimated that 5% of adults suffered from depression across the globe. Thus, the increase in prevalence of chronic diseases such as epilepsy, depression, and chronic pain, is driving the demand for VNS devices to manage and treat the disease.
However, high costs associated with vagus nerve stimulator devices and the lack of skilled personnel in some countries hinder market growth to some extent. In addition, many people in underdeveloped nations are not aware of the importance of vagus nerve stimulation therapy and do not understand the potential benefits of these treatments; which can also limit the market growth.
Moreover, development and technological advancements in vagus nerve stimulation devices provide growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions during the forecast period. There have been significant advancements in VNS technology such as the development of minimally invasive devices and closed-loop systems that adjust the stimulation based on patient needs. For instance, Soterix Medical Inc. introduced the first transcutaneous auricular vagus nerve stimulator (taVNS), which provides the necessary pulse parameter settings and offers portable option to modulate the vagus system. These technological advancements have improved the effectiveness and accessibility of VNS therapy which is expected to drive the market growth. Furthermore, surge in awareness among healthcare providers and patients about benefits of VNS therapy, to treat a variety of conditions, is further driving demand for VNS devices.
The global vagus nerve stimulation market is segmented into product, application, end user, and region. By product, the market is categorized into implantable VNS devices and external VNS devices. By application, the market is classified into epilepsy, depression, and others. By end user, the market is classified into hospitals, neurology clinics, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global vagus nerve stimulation market are Beijing PINS Medical Co., Ltd, Cirtec, electroCore, Inc., LivaNova PLC, MicroTransponder Inc., tVNS Health GmbH, Parasym Ltd, Neuropix Company Ltd., Soterix Medical Inc., and SetPoint Medical.
Vagus nerve stimulation (VNS) is a medical treatment that involves the use of electrical impulses to stimulate the vagus nerve, which is a large nerve that runs from the brainstem to the abdomen. The vagus nerve is responsible for regulating many important physiological functions, including heart rate, digestion, and breathing. The implantable device is typically implanted under the skin in the chest or neck, and a wire is attached to the vagus nerve. The electrical impulses generated by this device can help to regulate various physiological functions in the body, including heart rate, breathing, and digestion. VNS therapy is currently used to treat several medical conditions, including epilepsy, depression, and migraine.
VNS is generally considered safe and well-tolerated, although there are some side effects such as hoarseness, coughing, change in voice, and neck pain. These devices are of two types such as implantable VNS devices and externally VNS devices. Vagus nerve stimulation has been FDA-approved treatment for epilepsy and depression. In addition, compared to traditional medications, electrical stimulation of nerves can offer several advantages, such as targeted and adjustable stimulation, reduces risk of systemic side effects, and the potential for long-term benefits.
The global vagus nerve stimulation market is majorly driven by rise in number of people suffering from epilepsy and rise in technological advancements in vagus nerve stimulation devices. For instance, in 2021, Centers for Disease Control and Prevention (CDC), estimated that 5% of adults suffered from depression across the globe. Thus, the increase in prevalence of chronic diseases such as epilepsy, depression, and chronic pain, is driving the demand for VNS devices to manage and treat the disease.
However, high costs associated with vagus nerve stimulator devices and the lack of skilled personnel in some countries hinder market growth to some extent. In addition, many people in underdeveloped nations are not aware of the importance of vagus nerve stimulation therapy and do not understand the potential benefits of these treatments; which can also limit the market growth.
Moreover, development and technological advancements in vagus nerve stimulation devices provide growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions during the forecast period. There have been significant advancements in VNS technology such as the development of minimally invasive devices and closed-loop systems that adjust the stimulation based on patient needs. For instance, Soterix Medical Inc. introduced the first transcutaneous auricular vagus nerve stimulator (taVNS), which provides the necessary pulse parameter settings and offers portable option to modulate the vagus system. These technological advancements have improved the effectiveness and accessibility of VNS therapy which is expected to drive the market growth. Furthermore, surge in awareness among healthcare providers and patients about benefits of VNS therapy, to treat a variety of conditions, is further driving demand for VNS devices.
The global vagus nerve stimulation market is segmented into product, application, end user, and region. By product, the market is categorized into implantable VNS devices and external VNS devices. By application, the market is classified into epilepsy, depression, and others. By end user, the market is classified into hospitals, neurology clinics, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global vagus nerve stimulation market are Beijing PINS Medical Co., Ltd, Cirtec, electroCore, Inc., LivaNova PLC, MicroTransponder Inc., tVNS Health GmbH, Parasym Ltd, Neuropix Company Ltd., Soterix Medical Inc., and SetPoint Medical.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vagus nerve stimulation market analysis from 2022 to 2032 to identify the prevailing vagus nerve stimulation market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the vagus nerve stimulation market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global vagus nerve stimulation market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Implantable VNS devices
- External VNS devices
By Application
- Epilepsy
- Depression
- Others
By End user
- Hospitals
- Neurology clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
Key Market Players
- Beijing PINS Medical Co., Ltd
- electroCore, Inc.
- LivaNova PLC
- MicroTransponder Inc.
- Neuropix Company Ltd.
- Parasym Ltd
- SetPoint Medical Corporation
- Soterix Medical Inc.
- tVNS Health GmbH
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: VAGUS NERVE STIMULATION MARKET, BY PRODUCT
CHAPTER 5: VAGUS NERVE STIMULATION MARKET, BY APPLICATION
CHAPTER 6: VAGUS NERVE STIMULATION MARKET, BY END USER
CHAPTER 7: VAGUS NERVE STIMULATION MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Beijing PINS Medical Co., Ltd
- electroCore, Inc.
- LivaNova PLC
- MicroTransponder Inc.
- Neuropix Company Ltd.
- Parasym Ltd
- SetPoint Medical Corporation
- Soterix Medical Inc.
- tVNS Health GmbH
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
